Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Januar 2026 18:01 ET | Quelle: Ascendis Pharma

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones....
09. Januar 2026 16:50 ET | Quelle: Attindas Hygiene Partners

Attindas Hygiene Partners espande la sua posizione europea con un'acquisizione chiave

RALEIGH, Carolina del Nord, Jan. 09, 2026 (GLOBE NEWSWIRE) -- La strategia di crescita di Attindas Hygiene Partners ha compiuto oggi un importante passo avanti con l'acquisizione di Società Italiana...
09. Januar 2026 15:38 ET | Quelle: Gastro Center of Maryland

Gastro Center of Maryland Expands Columbia Team with New Board-Certified Gastroenterologists

COLUMBIA, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Gastro Center of Maryland is pleased to announce the addition of new board-certified gastroenterologists to its Columbia location at 7120 Minstrel...
09. Januar 2026 11:24 ET | Quelle: Angels My Way Home Care

Angels My Way Home Care Celebrates 15th 5-Star Google Review, Reinforcing Role as Best Home Health Care Service in Hamilton, Ontario

Hamilton, Ontario, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Angels My Way Home Care, a leading provider of professional and personalized home health care services in Ontario, proudly announces the...
09. Januar 2026 11:20 ET | Quelle: SEED Therapeutics

SEED Therapeutics Doses First Patient in Phase 1 Trial of ST-01156, a Molecular Glue Degrader Targeting RBM39

First-in-human study evaluates safety, pharmacokinetics, biomarker analyses, target engagement, and anti-tumor activity in patients with advanced solid tumors ST-01156 has received U.S. FDA Orphan...
09. Januar 2026 09:08 ET | Quelle: Community Mental Health Association of Michigan

Community Mental Health Association of Michigan Applauds Court of Claims Ruling on MDHHS Mental Health Bidout Process

LANSING, Mich., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Yesterday, Judge Yates, in the Michigan Court of Claims, issued an opinion and order in response to a suit filed by a number of Community Mental...
09. Januar 2026 09:01 ET | Quelle: ENvue Medical, Inc.

ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research

TYLER, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) (NASDAQ: NAOV) (“ENvue,” “ENvue Medical” or the “Company”), a medical technology company specializing on the...
09. Januar 2026 09:01 ET | Quelle: Mordor Intelligence

Non-Invasive Prenatal Testing Market 2031 Projections show 13.26% CAGR as Early Genetic Screening Adoption Accelerates: 2026 Mordor Intelligence Report

Hyderabad, Jan. 09, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the non-invasive prenatal testing market is valued at USD 3.90 billion in 2025 and estimated to grow from USD 4.42...
09. Januar 2026 08:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

-White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to...
09. Januar 2026 08:30 ET | Quelle: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to...

Nächste Seite